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The current definition for generic medicinal products is
found in Directive 2001/83/EC, Article 10(2)(b), which
states that a generic medicinal product is a product
which has the same qualitative and quantitative com-
position in active substances and the same pharmaceu-
tical form as the reference medicinal product, and
whose bioequivalence with the reference medicinal pro-
duct has been demonstrated by appropriate bioavailabil-
ity studies.
The different salts, esters, ethers, isomers, mixtures
of isomers, complexes or derivatives of an active sub-
stance are considered to be the same active substance,
unless they differ significantly in properties with regard
to safety and/or efficacy.
Furthermore, the various immediate-release oral phar-
maceutical forms shall be considered to be one and the
same pharmaceutical form.
Concept of bioequivalence is fundamental: The pur-
pose of establishing bioequivalence is to demonstrate
equivalence in biopharmaceutics quality between the
generic medicinal product and a reference medicinal
product in order to allow bridging of preclinical tests
and of clinical trials associated with the reference med-
icinal product.
In bioequivalence studies, the plasma concentration
time curve is generally used to assess the rate and extent
of absorption. Selected pharmacokinetic parameters and
preset acceptance limits allow the final decision on bioe-
quivalence of the tested products.
A U C ,t h ea r e au n d e rt h ec o n centration time curve,
reflects the extent of exposure. Cmax, the maximum
plasma concentration or peak exposure, and the time to
maximum plasma concentration, tmax, are parameters
that are influenced by absorption rate.
In studies to determine bioequivalence after a single
dose, the parameters to be analysed are AUC(0-t), or,
when relevant, AUC(0-72h), and Cmax. For these para-
meters the 90% confidence interval for the ratio of the
test and reference products should be contained within
the acceptance interval of 80.00-125.00%. To be inside
the acceptance interval the lower bound should be ≥
80.00% when rounded to two decimal places and the
upper bound should be ≤ 125.00% when rounded to two
decimal places.
Evaluation of Generic medicinal product is also based
on the pharmaceutical quality of the active substance:
absence of impurities,.. and of the finished product :
reproducibility of the manufacturing process, stability,….
A table of the Antiretroviral drugs and of the Generics
available in Europe is presented.
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